Press Release | Mon Oct 21, 2013 9:16pm EDT

Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra® for Use in Adult Patients Living With Moderately to Severely Active Rheumatoid Arthritis

* Reuters is not responsible for the content in this press release.